Frontier IP Group Plc has announced that its portfolio company, The Vaccine Group (TVG), has appointed an Advisory Board to support the scale-up of its novel herpesvirus-based vaccine platform. The advisory board consists of three high-ranking veterinary experts with strong business experience and connections in the animal health sector. TVG has made significant progress in establishing a pipeline of vaccines for use in livestock, pets, and wildlife to tackle viral and bacterial pathogens that cause economic harm or pose a threat to human health. The advisory board members have extensive experience in veterinary health and business. TVG currently has 12 vaccines under development, targeting economically harmful and zoonotic diseases. The vaccines are based on the company's tunable herpesvirus-based platforms. Jeremy Salt, Chief Executive of TVG, expressed optimism about gaining the support of the advisory board, stating that it will be helpful as the company grows in the global animal health innovation sector.